Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NBIX) is a Healthcare stock trading at $158.23 (as of 2026-06-18), with a market capitalization of $15.92B and a trailing P/E of 24.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neurocrine Biosciences, Inc. develops and markets prescription pharmaceuticals for neurological, endocrine, and psychiatric disorders. Its commercial therapies include INGREZZA for tardive dyskinesia, ONGENTYS for Parkinson’s disease (as an adjunct to levodopa-based regimens), ORILISSA for endometriosis-related pain, and ORIAHNN for heavy menstrual bleeding from uterine fibroids, along with clinical programs in areas such as pediatric and adult epilepsy and major depressive disorder.

Valuation — source: SEC EDGAR (first-party)
Price$158.23
Market Cap$15.92B
P/E Ratio24.4
EV / EBITDA19.2
Price / Book4.67
Price / Sales5.13
DCF Value (model)$195.41
DCF Upside vs Price23.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.86B
Net Margin16.7%
Return on Equity19.6%
Current Ratio2.93
Revenue Growth (YoY)42.2%
EPS Growth (YoY)2362.5%
FCF Growth (YoY)152.7%
Financial Health — source: SEC EDGAR
Altman Z-Score8.57 (safe)
Valuation vs Sector & Industry
Stock P/E24.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector16.2%
vs Industry41.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($1.76B)
Institutional Holders Tracked10
Congressional Trades (recent)2
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOKyle W. Gano
Employees1,800
CountryUS
IPO Date1996-05-23

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Biogen Inc. (BIIB)
  • Incyte Corporation (INCY)
  • Moderna, Inc. (MRNA)
NBIX earnings history · NBIX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.